Deepa Jagadeesh
Overview
Explore the profile of Deepa Jagadeesh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
81
Citations
857
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kharfan-Dabaja M, Mohty R, Easwar N, Johnston P, Iqbal M, Epperla N, et al.
Bone Marrow Transplant
. 2025 Mar;
PMID: 40025178
Older patients with lymphoma are typically underrepresented in clinical trials with chimeric antigen receptor T cell (CAR T) therapy. In this multicenter, observational study we aimed to assess the safety...
2.
Zhao X, Jagadeesh D, Bodo J, Durkin L, Lindner D, Ondrejka S, et al.
EJHaem
. 2025 Jan;
6(1):e1080.
PMID: 39877932
Introduction: Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive lymphoma with a poor prognosis. AITL is associated with Epstein-Barr virus (EBV)-positive B cells in most cases, suggesting a possible...
3.
Goyal A, OLeary D, Dabaja B, Weng W, Zain J, Cutler C, et al.
Transplant Cell Ther
. 2024 Sep;
30(11):1047-1060.
PMID: 39222792
Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma (CTCL). While MF generally follows an indolent course, a subset of patients will experience...
4.
Wierda W, Shah N, Cheah C, Lewis D, Hoffmann M, Coombs C, et al.
Lancet Haematol
. 2024 Jul;
11(9):e682-e692.
PMID: 39033770
Background: Richter transformation usually presents as an aggressive diffuse large B-cell lymphoma, occurs in up to 10% of patients with chronic lymphocytic leukaemia, has no approved therapies, and is associated...
5.
Bhansali R, Ellin F, Relander T, Cao M, Li W, Long Q, et al.
Blood Adv
. 2024 May;
8(13):3507-3518.
PMID: 38739715
Little is known about risk factors for central nervous system (CNS) relapse in mature T-cell and natural killer cell neoplasms (MTNKNs). We aimed to describe the clinical epidemiology of CNS...
6.
Stuver R, Mian A, Brown S, Devlin S, Caimi P, Chinapen S, et al.
Am J Hematol
. 2024 Mar;
99(6):1180-1183.
PMID: 38526002
No abstract available.
7.
Soumerai J, Diefenbach C, Jagadeesh D, Asch A, Kumar A, Tsai M, et al.
Br J Haematol
. 2024 Mar;
204(5):1762-1770.
PMID: 38500476
The combination of the phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor zandelisib with the Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib was hypothesized to be synergistic and prevent resistance to single-agent therapy. This...
8.
Hill B, Chen Y, Jagadeesh D, Dean R, Koc O, Boughan K, et al.
Leuk Lymphoma
. 2024 Mar;
65(6):768-773.
PMID: 38456694
Lenalidomide and rituximab (R) is an effective frontline treatment for patients with indolent B-cell non-Hodgkin lymphoma (iNHL). We investigated the safety and efficacy of addition of the proteasome inhibitor ixazomib...
9.
Alhaj Moustafa M, Ramdial J, Tsalatsanis A, Khimani F, Dholaria B, Bojanini L, et al.
Transplant Cell Ther
. 2024 Mar;
30(5):516.e1-516.e10.
PMID: 38431075
Hepatosplenic T-cell lymphoma (HSTCL) is a rare and aggressive type of peripheral T-cell lymphoma with median overall survival (OS) of approximately 1 year. Data on the effectiveness of hematopoietic cell...
10.
Karmali R, Galvez C, Hamadani M, Gordon L, Winter J, Ma S, et al.
Blood Adv
. 2024 Jan;
8(7):1612-1620.
PMID: 38237077
MYC-aberrant non-Hodgkin lymphoma (NHL) is associated with poor outcomes with conventional chemotherapy. Ixazomib is an orally bioavailable proteasome inhibitor that targets drivers of MYC expression and has demonstrated preclinical activity...